MedDataX Logo

Uric Acid Study in Healthy Male Volunteers

NCT ID: NCT00738842

Last Updated: 2010-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-05-31

Study Completion Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being conducted to examine the effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gout Coronary Artery Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Uric Acid Level

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

AZD6140

Intervention Type DRUG

Oral tablets taken bid for 5 days

2

Group Type PLACEBO_COMPARATOR

Placebo to match AZD6140

Intervention Type DRUG

Oral tablets taken bid for 5 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD6140

Oral tablets taken bid for 5 days

Intervention Type DRUG

Placebo to match AZD6140

Oral tablets taken bid for 5 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Normal physical examination, vital signs, electrocardiogram (ECG) and laboratory values (unless the investigator considers an abnormality not to be clinically significant)
* Normal laboratory tests at screening
* Non-smoker (no cigarette/tobacco use for at least 6 months)

Exclusion Criteria

* Personal or family history of gout, gouty arthritis, or renal stones
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca Pharmaceuticals

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kathleen Butler, MD

Role: STUDY_DIRECTOR

AstraZeneca

Stuart Harris, MD

Role: PRINCIPAL_INVESTIGATOR

SeaView Research

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D5130C00050

Identifier Type: -

Identifier Source: org_study_id